{
    "timestamp": "Sep 4, 2025 8:11 AM EST",
    "stats": {
        "input_words": 716769,
        "output_words": 273,
        "filings_processed": 4
    },
    "filings": [
        {
            "company_name": "Cisco",
            "stock": "CSCO",
            "wiki_url": "https://en.wikipedia.org/wiki/Cisco",
            "change_percent": 0,
            "price": 67.67,
            "filing_type": "10-K",
            "filing_time": "2025-09-03T16:52:59-04:00",
            "filing_url": "https://www.sec.gov/Archives/edgar/data/858877/000085887725000111/0000858877-25-000111-index.htm",
            "accession_number": "0000858877-25-000111",
            "summary_points": [
                "1.  As of July 26, 2025, $1.6 billion in unrecognized tax benefits could impact the effective tax rate if realized.",
                "2.  The company's net deferred tax assets were $7.281 billion as of July 26, 2025, compared to $6.186 billion on July 27, 2024.",
                "3.  A $355 million charge was recorded in the fourth quarter of fiscal 2025 (ending July 26, 2025) due to a legal settlement with a supplier, offset by an $82 million income tax benefit."
            ]
        },
        {
            "company_name": "Salesforce",
            "stock": "CRM",
            "wiki_url": "https://en.wikipedia.org/wiki/Salesforce",
            "change_percent": 0,
            "price": 256.47,
            "filing_type": "10-Q",
            "filing_time": "2025-09-03T21:41:22-04:00",
            "filing_url": "https://www.sec.gov/Archives/edgar/data/1108524/000110852425000088/0001108524-25-000088-index.htm",
            "accession_number": "0001108524-25-000088",
            "summary_points": [
                "Failed to analyze filing"
            ]
        },
        {
            "company_name": "Elevance Health",
            "stock": "ELV",
            "wiki_url": "https://en.wikipedia.org/wiki/Elevance_Health",
            "change_percent": 0,
            "price": 321.56,
            "filing_type": "8-K",
            "filing_time": "2025-09-04T06:02:07-04:00",
            "filing_url": "https://www.sec.gov/Archives/edgar/data/1156039/000115603925000129/0001156039-25-000129-index.htm",
            "accession_number": "0001156039-25-000129",
            "summary_points": [
                "1. Elevance Health, Inc. reaffirmed its 2025 shareholders' earnings guidance to be approximately $24.10 per diluted share, with adjusted earnings (excluding approximately $5.90 per diluted share of net unfavorable items) expected to be approximately $30.00 per diluted share.",
                "2.  The company anticipates a benefit expense ratio of approximately 90.0% for the full year 2025.",
                "3.  Elevance Health's actual results could materially differ from its current guidance due to changes in business factors or assumptions, including cost trends and medical claims payable estimates."
            ]
        },
        {
            "company_name": "Cencora",
            "stock": "COR",
            "wiki_url": "https://en.wikipedia.org/wiki/Cencora",
            "change_percent": 0,
            "price": 295.03,
            "filing_type": "8-K",
            "filing_time": "2025-09-03T16:43:27-04:00",
            "filing_url": "https://www.sec.gov/Archives/edgar/data/1140859/000110465925087080/0001104659-25-087080-index.htm",
            "accession_number": "0001104659-25-087080",
            "summary_points": [
                "1. On September 3, 2025, Cencora, Inc. announced a settlement agreement, subject to court approval, resolving a stockholder derivative action related to oversight of controlled substance diversion programs; insurance carriers will pay the company $111.3 million, less any attorneys' fees and expenses.",
                "2. The settlement agreement, filed on August 15, 2025, and subject to court approval by November 13, 2025, involves a $111.3 million payment to Cencora, Inc.  This is a significant sum, representing a considerable portion of the company\u2019s potential liability.",
                "3.  The court approval process for the settlement agreement presents a risk to Cencora, Inc.; if the court rejects the settlement, the company faces continued legal costs and uncertainty regarding the final outcome of the lawsuit."
            ]
        }
    ]
}